Large Law Firm Practice and Management

Thomson Reuters Corporation's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version


/ Untapped potential for the pharmaceutical industry in the treatment of depression

Untapped potential for the pharmaceutical industry in the treatment of depression

Our new analyses explore the impact of Prozac and the current state of the depression treatment environment

11 Jul 2014

A tourist visits Hirbet Madras archaeological site, featuring ancient rebel hideouts, at the foothills of Jerusalem around the ancient city of Beit Guvrin August 23, 2011. Caption|REUTERS/Baz Ratner

The U.S. release of the anti-depressant Prozac in 1988 ushered in a new class of pharmaceuticals. Two years after its launch, the product became the world’s most prescribed medication and a pop-culture phenomenon, putting society on a path to destigmatized depression.

According to the World Health Organization, however, depression is still the leading cause of disability globally. How has treatment changed in the past 25 years and where is the industry headed?

Our analysts studied the widespread effects of Prozac and the current state of the depression treatment environment using pharmaceutical data from Cortellis™ Competitive Intelligence and Thomson Reuters Recap, patent information from Thomson Innovation® and Derwent® World Patents Index, and analyzed research highlights from Web of Science℠ provided by our ScienceWatch analysts. The three unique analyses include:

  • 25 Years After Prozac,an infographic illustrating a timeline from the 1988 launch to a current outlook at the condition’s prevalence rates and drug, patent and deal landscapes. 
  • Spotlight on Depression, an in-depth report exploring the challenges and opportunities facing the depression drug market and a look at its current leaders
  • Battling Depression: Research Highlights, a view into the dominant research around treatments for depression

Our analysts found a substantial number of possibilities for the pharmaceutical market for developing new treatments for the management of depression. It remains a significant global health issue. The high incidence rate, combined with limited market penetration, continues to make depression a market with considerable potential.

Depression and Treatment History. Thomson Reuters Spotlight on Depression and 25 years after Prozac.

The analysts also found that despite the growing market opportunities, companies developing drugs for depression face several challenges.

Challenges for antidepressant medications

“Depression is widespread, but clinicians still lack a complete understanding of the condition, which presents hurdles in pharmaceutical development,” said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences. “There are millions of people around the world who suffer from depression every day. The aim of this report is to shed a unique perspective on the evolution of depression therapies in hopes that it incents the industry to identify new ways to help depression sufferers manage their condition.”

Learn more

View the full reports:

Find out more about the solutions behind the data: Cortellis Competitive Intelligence, Thomson Reuters Recap, DerwentWorld Patents Index, Thomson Innovation, Web of Science℠

News Source : Large Law Firm Practice and Management
Copy this html code to your website/blog to embed this press release.